The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global’s (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia
  • Canntab Therapeutics has been given the green light by Health Canada, meaning Cann Global can begin importing the products
  • The patented pills from Canntab are unique as they allow for precise dosing
  • CGB plans to order six different products from the pill range
  • Among the pills Cann Global has ordered are two THC products, two CBD products and two THC/CBD blends
  • The products will begin arriving in Australia next month and will be available through the Special Access Scheme B and Authorised Prescriber schemes
  • Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share

Cann Global’s (CGB) joint venture (JV) partner has been handed a key export permit, which will allow its cannabis hard pills to be shipped to Australia.

Canntab Therapeutics has been given the green light by Health Canada, while Cann Global has already secured the necessary import permits for the pills.

Following the export permit being issued, Cann advises that its order of the hard pill products will begin arriving in Australia next month.

Canntab’s products are unique because of the patented hard pill form which they come in, which allows for more precise dosing.

CGB has ordered six different products from its JV partner, including two THC products, two CBD products and two THC/CBD blends.

The CBD and THC pills will be available in Australia through both the Special Access Scheme B and Authorised prescriber schemes.

Cann is also planning to make the pills available to the Cannabinoid Medicine Observational Study (CMOS) which is testing the efficacy of cannabis on neurological and mental health conditions.

Shares in Cann Global have opened Tuesday trading steady at 0.8 cents per share at 10:06 am AEDT.

CGB by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…